Managing diabetes effectively often involves regular insulin administration, which can be challenging for patients due to the need for frequent injections. That’s why we’re dedicated to providing patients with an alternative: fully noninvasive insulin through transdermal application.

The USA Leaders magazine has featured our CEO, Jan Henk Hendriks, as one of the “10 most influential pharma leaders of 2024”!

We are pleased to announce that our CEO, Jan Hendriks, will be representing our company at the highly anticipated BIO CEO & Investor Conference in New York City on February 27-28!

We are thrilled to announce our active participation in the upcoming 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Tech Fair, scheduled to take place in Florence from 6th to 9th March 2024.

Jan Hendriks, CEO of Biotts, will be at JPM Week 2024, and he’s eager to connect with investors interested in our revolutionary, patented transdermal drug delivery technology. Don’t miss the chance to explore partnership opportunities and discuss the future of drug delivery!

We are pleased to share the news of our strategic collaboration with BIOTON S.A. Together, we embark on a groundbreaking proof-of-concept project aimed at transdermal insulin delivery – a pioneering initiative set to make history.